A new ¹¹¹in‐bleomycin complex for combined radiotherapy and chemotherapy

Abstract

Six days after tumor transplantation three daily intraperitoneal doses of 0.9% NaCl, bleomycin (BLM), or a new 111In-bleomycin complex (BLMC, 15 microCi/g body weight) were administered to glioma-bearing mice. After therapy, tumors in mice treated with 111In-BLMC were smaller than those treated with BLM. Sixteen days after the first injection tumor size for 111In-BLMC-treated mice was 560 (240-1,030) mm3, 1,980 (1,400-3,290) mm3 for BLM (P less than 0.025), and 4,830 (2,580-9,180) mm3 for NaCl (0.1 less than P less than 0.2). Thirteen days after tumor transplantation glioma-bearing mice received single intratumor injection of 0.9% NaCl, BLM, or 111In-BLMC (1.5 mCi, carried by 0.5 mg BLM/g tumor weight). The average tumor size for 111In-BLMC was smaller than that for BLM by a factor of 2.5-3.7. Host weights for these two groups were similar, and morphologic abnormalities were not found in kidney or liver.

Chromosome aberrations of human small cell lung cancer induced by a new 111in‐bleomycin complex

“…The final pH was 2.5 (2.0-3.0) by pH paper (pHydrion paper, Micro Essential Laboratory, Brooklyn, NY) [7] or a pH meter and then was quality controlled by thin-layer chromatography (TLC) and 5% gel electrophoresis [5,7]. The radiochemical purity of "'In-BLMC was 99%.…”

“…It also depressed tumor growth for a transplanted glioma [7]. These indicated a potential cytotoxic effect of the radiolabeled drug as well as the ability to localize in tumor.…”

Auger processes in the 21st century

“…This approach implements a chemotherapy agent that is labeled with an Auger electron emitter (Hou et al 1985, Howell et al 1986, Azure et al 1992). Garnuszek (2004) has produced a Pt(II)Cl 2 - 125 I-histamine complex and tested its capacity to inhibit the growth of transplantable colon carcinoma (C38) in mice.…”

A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: Validation with daunomycin, doxorubicin, and the alpha particle emitter 210Po

“…Over the past three decades, a significant effort has been directed toward achieving improvements in treatment of cancer with radioimmunotherapy [1–3], radiolabeled chemotherapy agents [4–8], and a combination of chemotherapy with radioimmunotherapy [9, 10]. Although considerable successes have been realized with targeted radionuclide therapy and translated into front-line therapies [2], the full potential of this therapeutic modality has yet to be realized.…”